Replimune (REPL) Liabilities and Shareholders Equity (2018 - 2026)

Replimune (REPL) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $332.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 39.71% year-over-year to $332.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 30.31% YoY), and the FY2026 full-year result was $332.4 million, down 39.71% from the prior year.
• Liabilities and Shareholders Equity was little changed at $332.4 million in Q1 2026, from $333.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $678.6 million in Q4 2022 to a low of $332.4 million in Q1 2026.
• A 5-year average of $504.8 million and a median of $498.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 40.2% in 2023 and plunged 44.74% in 2025, its largest moves.
• Tracing REPL's Liabilities and Shareholders Equity over 5 years: stood at $678.6 million in 2022, then decreased by 21.46% to $532.9 million in 2023, then increased by 13.27% to $603.6 million in 2024, then tumbled by 44.74% to $333.6 million in 2025, then decreased by 0.36% to $332.4 million in 2026.
• Business Quant data shows REPL's Liabilities and Shareholders Equity at $332.4 million in Q1 2026, $333.6 million in Q4 2025, and $389.4 million in Q3 2025.